Inhalant use, unspecified with unspecified inhalant-induced disorder
ICD-10 F18.99 is a billable code used to indicate a diagnosis of inhalant use, unspecified with unspecified inhalant-induced disorder.
F18.99 refers to inhalant use that is unspecified, accompanied by an unspecified inhalant-induced disorder. Inhalants are substances that produce chemical vapors, which can be inhaled to induce psychoactive effects. Common inhalants include solvents, aerosols, gases, and nitrites. The use of these substances can lead to a range of health issues, including neurological damage, respiratory problems, and psychological disorders. The unspecified nature of this code indicates that the specific inhalant used and the exact nature of the disorder are not clearly defined. Clinicians may encounter patients with varying degrees of inhalant use, from casual use to severe addiction, and may present with symptoms of intoxication, withdrawal, or other mental health issues. Treatment often involves behavioral therapies, counseling, and support groups, as well as medical interventions for any physical health complications arising from inhalant use. Accurate coding is essential for appropriate treatment planning and insurance reimbursement.
Detailed history of substance use, including types of inhalants, frequency, and duration of use.
Patients presenting with acute intoxication, withdrawal symptoms, or co-occurring mental health disorders.
Consideration of comorbid conditions and the need for multidisciplinary treatment approaches.
Comprehensive psychiatric evaluation, including mental status examination and assessment of substance use history.
Patients with inhalant use presenting with anxiety, depression, or psychotic symptoms.
Assessment of risk factors for substance use disorders and the impact on overall mental health.
Used in conjunction with treatment for inhalant use disorder.
Document the counseling session details and patient progress.
Addiction specialists may need to coordinate care with mental health providers.
Document the patient's history of inhalant use, specific symptoms experienced, any treatment provided, and the impact on their daily functioning.
